Coordinated Treatment of Addiction to Prescription Pain Medications

处方止痛药成瘾的协调治疗

基本信息

批准号：
8927278
负责人：
Mary P Metcalf
金额：
$ 38.89万
依托单位：
CLINICAL TOOLS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-15 至 2018-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8927278
关键词：
Address Agreement Alcohol or Other Drugs use Analgesics Archives Attention Attitude Awareness Behavior Behavior Control Buprenorphine Clinic Clinical Communication Communication Tools Competence Complex Data Data Collection Development Drug Addiction Drug Prescriptions Drug usage Education Electronic Health Record Evaluation Evaluation Reports Feedback Genetic Crossing Over Goals Health Health Insurance Portability and Accountability Act Health Personnel Health Professional Housing Illicit Drugs Interview Knowledge Lead Location Measures Methodology Monitor Morbidity - disease rate Online Systems Opiate Addiction Opioid Outcome Outcome Assessment Outcome Measure Outpatients Overdose Oxycodone Pain Participant Patient Care Patients Pharmaceutical Preparations Phase Physicians Pilot Projects Primary Health Care Procedures Process Production Provider Publishing Randomized Recruitment Activity Reporting Research Design Role Self Efficacy Services Site Speed Staging Structure Surveys Testing Time Training Training Support Urine Visit Waiting Lists Work addiction base data sharing design drug seeking behavior drug testing evaluation/testing expectation experience health care service organization heuristics improved instrument member mortality novel patient oriented phase 2 study preference prescription opioid privacy protection prototype satisfaction skills skills training tool usability

项目摘要

DESCRIPTION (provided by applicant): In 2010, more than 12 million people reported using prescription pain medications (opioids) non-medically (without a prescription) [1], and 2 million people reported using prescription painkillers non-medically for the first time [1]. In 2009, 1/3 o people older than 12 initiated illicit drug use via non-medical use of prescription drugs [2]. Each year the problem results in more morbidity and mortality (often due to accidental overdose). Office-based opioid treatment (OBOT) with buprenorphine can break the cycle of addiction to opioids. Unfortunately, the quality and availability of treatment for prescription opioid addiction varies, and involves novel agreements and testing (e.g., urine drug testing). Patients must also navigate a complex treatment process with special concerns and unique challenges including fixed and frequent outpatient visits, and following standard procedures to limit diversion and misuse of buprenorphine. Our existing and successful PC/mobile web-based provider education product has provided training to thousands of physicians on the proper prescribing of buprenorphine. In this project, we seek to add a novel supporting framework for patients in treatment for opioid prescription drug addiction called The BupPractice.com: Patient Support Center. Components include: 1. Patient and provider matched data collection and communication functionality to facilitate open and accurate communication and allow the patient and provider to work in tandem to treat opioid addiction. Via the functionality they can collect and communicate patient data, request information, and communicate plans. We will investigate integrating our service into an EMR; 2. A patient support extension that provides patients with the knowledge, skills, encouragement, and awareness to fully participate in OBOT; 3. Additional provider training to assist providers in implementing a more patient-centered approach. Phase I focuses on product design work, developing prototype tools, measuring acceptability and usability of the product, and Phase II planning including finalizing evaluation test sites. Phase I completes the product and evaluates its impact using a randomized, cross-over wait-list control design to assess impact, including effect on patient outcomes. We will specifically assess: 1. Short term impact on patient's knowledge, self-efficacy, attitude, and satisfaction, 2. Providers' acceptability and satisfaction with the experience, and 3. Patient outcomes using standardized instruments such as the Brief Addiction Monitor (BAM), and a checklist of required patient behaviors to be completed by the providers. The finalized Phase II product will be integrated it into an electronic health record in one of our evaluation sites.

描述（由申请人提供）：2010年，超过1200万人非医疗（无处方）使用处方止痛药（阿片类药物）[1]，2000万人首次非医学上使用处方止痛药[1] [1]。在2009年，1/3 O人以外的人通过非医学使用处方药来开始使用非法药物[2]。每个一年，问题会导致更多的发病率和死亡率（通常是由于意外过量引起的）。基于办公室的阿片类药物治疗（OBOT）用丁丙诺啡可以打破对阿片类药物成瘾的周期。不幸的是，处方阿片类药物成瘾的治疗质量和可用性变化，涉及新的协议和测试（例如尿液药物测试）。患者还必须在复杂的治疗过程中进行特殊问题和独特的挑战，包括固定和频繁的门诊就诊，并遵循限制丁丙诺啡的转移和滥用的标准程序。我们现有且成功的基于PC/移动Web的提供商教育产品已为成千上万的医生提供了丁丙诺啡的适当处方培训。在这个项目中，我们试图为患者添加一个新颖的支持框架，用于治疗阿片类药物处方药成瘾，称为buppractice.com：患者支持中心。组件包括：1。患者和提供者匹配的数据收集和通信功能，以促进开放和准确的沟通，并允许患者和提供者协同工作以治疗阿片类药物成瘾。通过功能，他们可以收集和传达患者数据，请求信息并传达计划。我们将调查将服务集成到EMR中； 2。为患者提供知识，技能，鼓励和意识以充分参与OBOT的患者支持扩展； 3。其他提供者培训，以帮助提供者实施以患者为中心的方法。第一阶段的重点是产品设计工作，开发原型工具，衡量产品的可接受性和可用性以及II期计划，包括最终评估测试站点。第一阶段完成了产品并使用随机的，交叉的等待列表控制设计来评估其影响，以评估影响影响，包括对患者预后的影响。我们将具体评估：1。对患者知识，自我效能感，态度和满意度的短期影响，2。提供者对体验的可接受性和满意度，以及3。使用标准化工具（例如简短成瘾监护仪（BAM）（BAM）以及所需的患者行为清单的患者结果。最终的II期产品将在我们的一个评估站点中将其集成到电子健康记录中。